Growth-Differentiation Factor-15 and Major Cardiac Events

Lin, Jeng-Feng; Wu, Semon; Hsu, Shun‐Yi; Yeh, Kuan‐Hung; Chou, Hsin-Hua; Cheng, Shih‐Tsung; Wu, Tien-Yu; Hsu, Wen-Tze; Yang, Chun‐Chun; Ko, Yu‐Lin

doi:10.1097/maj.0b013e318291cd4e

Cited by 30 publications

(19 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surprisingly, in individuals before T2DM manifestation the concentration of GDF-15 was not independently associated with incident T2DM in follow up period [47]. Inversely, elevated GDF-15 has demonstrated a predictive value for CV complications, all cause mortality and CV mortality in diabetic individuals with established CV diseases, nephropathy, hypertension, rheumatic diseases [37, [48][49][50]. Overall these findings indicate that clinically significance of similar associations between circulating levels of anti-inflammatory cytokines.…”

Section: Page 5 Of 11mentioning

confidence: 81%

Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15

Berezin

2016

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

Section: Page 5 Of 11mentioning

confidence: 81%

Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15

Berezin

2016

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

“…The eligible trials involved a total of 53 706 participants. Six studies enrolled community‐based populations, 17 studies were restricted to patients with coronary artery disease (CAD), five studies were on HF, and the remaining three were respectively pertaining to diabetes mellitus (DM), atrial fibrillation (AF) and intensive care unit patients . The mean age of the subjects ranged from 42 to 79 years.…”

Section: Resultsmentioning

confidence: 99%

“…Table showed the estimates of association between GDF‐15 levels and risk of adverse outcomes included in the meta‐analysis. Nineteenstudies individually regarded the GDF‐15 level as a continuous variable to evaluate the risk of CVDs, 7 studies only regarded the GDF‐15 level as a categorical variable and 5 studies utilized both two ways. Among the 31 trials, seven reported CVD mortality as outcomes, 13 reported complex adverse outcome, and 20 reported all‐cause mortality as outcomes.…”

Section: Resultsmentioning

confidence: 99%

Growth differentiation factor‐15 and the risk of cardiovascular diseases and all‐cause mortality: A meta‐analysis of prospective studies

Xie

Liu

2019

Clinical Cardiology

View full text Add to dashboard Cite

Background and Aim Previous studies have documented that the association between growth differentiation factor‐15 (GDF‐15) the risk of patients with cardiovascular diseases (CVDs). In this meta‐analysis, our main objective is to explore the associations between GDF‐15 and the risk of CVD or all‐cause mortality. Methods PubMed and ISI Web of Science (up to January 2018) electronic databases were browsed for eligible studies. The studies provided relevant data depicted as hazard ratio (HR) with 95% confidence interval (CI), with regard to the association between GDF‐15 levels and subsequent risk of CVDs or all‐cause mortality. A random‐effect model was applied to pool the HR and 95% CI. Results Thirty‐one prospective studies met the eligibility criteria involving 53 706 subjects with 7020 adverse outcome events. It was concluded that GDF‐15 levels were associated with an incremental risk of CVDs or all‐cause mortality. Highest GDF‐15 category was associated with greater risk of cardiovascular mortality (HR, 2.66; 95% CI, 1.69‐3.63), all‐cause mortality (HR, 2.52; 95% CI, 2.06‐2.97), and complex adverse outcome (HR, 1.81; 95% CI, 1.42‐2.21). As each log‐unit increment in GDF‐15 concentration, the corresponding risk of adverse events also escalated, cardiovascular mortality (HR, 2.11; 95% CI, 1.57‐2.66), all‐cause mortality (HR, 2.70; 95% CI, 2.29‐3.12), and complex adverse outcome (HR, 1.96; 95% CI, 1.64‐2.29). Conclusions Judging from the results of the data analysis, GDF‐15 levels may increase the risk of CVDs or all‐cause mortality.

show abstract

“…GDF-15 has been introduced as a biomarker for cardiovascular events and cardiovascular risk stratification [42-44] and several vascular diseases including STEMI [42], coronary artery disease [43, 45], stroke [46] as well as renal and cardiac damage in general [47-49]. In addition to its value as a surrogate parameter, an active role in atherosclerosis and other vascular pathologies has been suggested [50, 51].…”

Section: Discussionmentioning

confidence: 99%

Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro

et al. 2017

View full text Add to dashboard Cite

Background: Vascular calcification is a common phenomenon in patients with chronic kidney disease and strongly associated with increased cardiovascular mortality. Vascular calcification is an active process mediated in part by inflammatory processes in vascular smooth muscle cells (VSMC). These could be modified by the insufficient removal of proinflammatory cytokines through conventional high-flux (HF) membranes. Recent trials demonstrated a reduction of inflammation in VSMC by use of dialysis membranes with a higher and steeper cut-off. These membranes caused significant albumin loss. Therefore, the effect of high retention Onset (HRO) dialysis membranes on vascular calcification and its implications in vitro was evaluated. Methods: In the PERCI II trial, 48 chronic dialysis patients were dialyzed using HF and HRO dialyzers and serum samples were collected. Calcifying VSMC were incubated with the serum samples. Calcification was determined using alizarin red staining (AZR) and determination of alkaline phosphatase (ALP) activity. Furthermore, apoptosis was evaluated, and release of matrix Gla protein (MGP), osteopontin (OPN) and growth differentiation factor 15 (GDF-15) were measured in cell supernatants. Results: Vascular calcification in vitro was significantly reduced by 24% (ALP) and 36% (AZR) after 4 weeks of HRO dialysis and by 33% (ALP) and 48% (AZR) after 12 weeks of dialysis using HRO membranes compared to HF dialysis. Apoptosis was significantly lower in the HRO group. The concentrations of MGP and OPN were significantly elevated after incubation with HF serum compared to HRO serum and healthy controls. Similarly, GDF-15 release in the supernatant was elevated after incubation with HF serum, an effect significantly ameliorated after treatment with HRO medium. Conclusions: Expanded haemodialysis therapy reduces the pro-calcific potential of serum from dialysis patients in vitro. With a markedly reduced albumin filtration compared to high cut-off dialysis, use of the HRO dialyzers may possibly provide a treatment option for chronic dialysis patients to reduce the progression of vascular calcification.

show abstract

Growth-Differentiation Factor-15 and Major Cardiac Events

Cited by 30 publications

References 34 publications

Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15

Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15

Growth differentiation factor‐15 and the risk of cardiovascular diseases and all‐cause mortality: A meta‐analysis of prospective studies

Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro

Contact Info

Product

Resources

About